Apr 24, 2018
FDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency in the market as an alternative to currently present intravenous drugs. The company specializes in ...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper